🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Colorado
Clinical trial register · United States · industry-sponsored

Clinical Trials in Colorado, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca88 Janssen Research & Development, LLC69 Eli Lilly and Company65 Merck Sharp & Dohme LLC64 Novartis Pharmaceuticals56
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in Colorado

2068 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array
NCT06598059Hearing Loss
DrugDexamethasone
Cochlear
Not applicable
56
California, Colorado, Iowa, Michigan, Missouri, New York, Ohio, Oregon
2025-01-03
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910Crohn's Disease
DrugsVedolizumab·Upadacitinib
Takeda
Phase 3
396
California, Colorado, Florida, Indiana, Kentucky, New York, South Carolina, South Dakota
2025-01-02
Recruiting
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
NCT06524830Treatment Resistant Depression
atai Therapeutics, Inc.
Phase 2
142
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland
2024-12-30
Recruiting
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
NCT06749457Staphylococcus Aureus
AstraZeneca
Phase 1/2
231
Alabama, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky
2024-12-30
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Colorado, Illinois, Ohio, Pennsylvania, Tennessee, Texas
2024-12-27
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
DrugAnvumetostat
Amgen
Phase 2
61
California, Colorado, Connecticut, District of Columbia, Louisiana, Michigan, Tennessee, Texas
2024-12-26
Recruiting
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
NCT06805695Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Urea Cycle Disorders, Inborn
iECURE, Inc.
Observational
13
Colorado, New York
2024-12-23
Recruiting
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379Major Depressive Disorder
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-12-20
Active, closed
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
NCT06653842Cutaneous Venous Malformations
Palvella Therapeutics, Inc.
Phase 2
15
California, Colorado, Maryland, Minnesota, North Carolina, Ohio, Pennsylvania, Utah
2024-12-20
Active, closed
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
NCT06718101Atopic Dermatitis
DrugLutikizumab
AbbVie
Phase 2
83
Arizona, California, Colorado, Florida, Illinois, Nebraska, New York, Oregon
2024-12-19
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics
Phase 3
1,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2024-12-19
Active, closed
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190Multifocal Motor Neuropathy (MMN), MMN
DrugsImmunoglobulin·IVIG·Empasiprubart
argenx
Phase 3
154
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-12-18
Active, closed
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT06696443Diabetic Peripheral Neuropathic Pain
DrugSuzetrigine
Vertex Pharmaceuticals Incorporated
Phase 3
455
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-12-18
Active, closed
A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
NCT06713239Coronary Artery Disease
Cleerly, Inc.
Not applicable
1,000
Alabama, California, Colorado, Florida, Illinois, Iowa, Kentucky, Louisiana
2024-12-18
Active, closed
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
NCT06564818Major Depressive Disorder
DrugCYB003
Cybin IRL Limited
Phase 3
220
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2024-12-17
Active, closed
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
NCT06712407IgA Nephropathy
Calliditas Therapeutics AB
Phase 4
60
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky
2024-12-17
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
240
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2024-12-17
Recruiting
Using CTA Measures to Define Cardiac Risk In NFL Alumni
NCT06831409Coronary Artery Disease (CAD), Heart Disease, Coronary Atherosclerosis
HeartFlow, Inc.
Observational
300
Colorado
2024-12-17
Recruiting
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
NCT06359041Generalized Myasthenia Gravis (gMG)
DrugCABA-201
Cabaletta Bio
Phase 1/2
24
California, Colorado, Florida, Illinois, Kansas, Massachusetts, Minnesota, New York
2024-12-17
Recruiting
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406Metastatic Uveal Melanoma
DrugsRP2·Ipilimumab·Nivolumab
Replimune, Inc.
Phase 2/3
280
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Iowa
2024-12-17
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 2
480
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-12-16
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Maine
2024-12-16
Active, closed
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT06710847Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer
GlaxoSmithKline
Phase 1/2
14
California, Colorado, Michigan, New York, Pennsylvania
2024-12-13
Active, closed
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma
DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine
Arcus Biosciences, Inc.
Phase 3
610
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-12-13
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Irinotecan·Pemetrexed
Janssen Research & Development, LLC
Phase 3
700
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-12-12
Recruiting
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
NCT06623890Friedreich Ataxia
DrugOmaveloxolone
Biogen
Observational
300
California, Colorado, Florida, Pennsylvania
2024-12-12
Recruiting
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619Asthma
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
724
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-12-12
Recruiting
Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation
NCT05945329Capsular Contracture Associated With Breast Implant, Capsular Contracture Grade III, Capsular Contracture Grade IV
C. R. Bard
Not applicable
250
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2024-12-12
Recruiting
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
NCT06636656Ulcerative Colitis
Boehringer Ingelheim
Phase 2
80
Arizona, Colorado, Florida, Illinois, Kansas, New York, North Carolina, Texas
2024-12-11
Active, closed
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)
NCT06741228Generalized Anxiety Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, New Jersey
2024-12-11
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
350
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-12-11
Recruiting
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
NCT06630234Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC
Phase 1/2
120
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Minnesota, New York
2024-12-10
Active, closed
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686Idiopathic Pulmonary Fibrosis (IPF)
Vicore Pharma AB
Phase 2
378
Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2024-12-09
Active, closed
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
NCT06645886Hematologic Malignancies, Adult
DrugsKQB198·Dasatinib
Kumquat Biosciences Inc.
Phase 1
13
California, Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2024-12-09
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140COVID-19 SARS-CoV-2 Infection
DrugIbuzatrelvir
Pfizer
Phase 3
2,330
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2024-12-08
Recruiting
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
NCT06768489Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
DrugsJNJ-79635322·Pomalidomide·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 1
240
Colorado, Georgia
2024-12-04
Recruiting
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
NCT06603844Solid Tumor
DrugTislelizumab
Corbus Pharmaceuticals Inc.
Phase 1/2
156
Alabama, Arizona, California, Colorado, Florida, Illinois, Minnesota, Nebraska
2024-12-04
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Michigan
2024-12-04
Active, closed
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
NCT06617429Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 3
129
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York
2024-12-03
Active, closed
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
NCT06685757Antibody-mediated Rejection
DrugFelzartamab
Biogen
Phase 3
132
California, Colorado, Illinois, Kansas, Louisiana, Minnesota, Missouri, Nebraska
2024-12-03
Active, closed
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
NCT06706622Multiple System Atrophy
H. Lundbeck A/S
Phase 3
401
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Indiana, Maryland
2024-12-03
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245Patients With Non-Small Cell Lung Cancer
DrugPaclitaxel
OSE Immunotherapeutics
Phase 3
363
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana
2024-12-03
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698Chronic Kidney Disease
DrugSemaglutide
Novo Nordisk A/S
Phase 2
465
California, Colorado, Florida, Illinois, Indiana, Michigan, Missouri, New York
2024-12-02
Active, closed
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805HIV Infections
DrugsRpv La·Cab La
ViiV Healthcare
Phase 3
326
Alabama, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2024-12-02
Recruiting
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700Coronavirus Disease (COVID-19)
DrugMolnupiravir
Merck Sharp & Dohme LLC
Phase 3
3,082
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-12-02
Active, closed
Retrospective PNS Study
NCT06832449Chronic Pain
Curonix LLC
Observational
200
Colorado
2024-12-01
Active, closed
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742Wet Age Related Macular Degeneration, wAMD
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
1,160
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-11-27
Active, closed
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918Neovascular Age-related Macular Degeneration
DrugsOtx-Tki·Aflibercept
Ocular Therapeutix, Inc.
Phase 3
825
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-27
Active, closed
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113Multiple Sclerosis
Novartis Pharmaceuticals
Phase 4
24
California, Colorado, Illinois, Massachusetts
2024-11-25
Active, closed
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
NCT06720038Pneumococcal Vaccines
Vaxcyte, Inc.
Phase 2
900
Arkansas, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Nebraska
2024-11-25
Active, closed
Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus
NCT06627517Type 1 Diabetes Mellitus, Sleep Quality
Luna Diabetes
Not applicable
120
California, Colorado, Minnesota
2024-11-22
Recruiting
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
NCT06690398Irritability Associated With Autism Spectrum Disorder
DrugLumateperone
Intra-Cellular Therapies, Inc.
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2024-11-22
Active, closed
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
NCT06693531Eosinophilic Esophagitis (EoE)
Regeneron Pharmaceuticals
Observational
368
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-11-22
Recruiting
Acellular Dermal Matrix Investigation in Breast Reconstruction
NCT06456554Breast Reconstruction
RTI Surgical
Not applicable
467
Arkansas, California, Colorado, Kansas, Missouri, New York, Ohio, Oklahoma
2024-11-22
Active, closed
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
NCT06668805Noonan Syndrome
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
30
California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-11-22
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
DrugsHLX22·Trastuzumab·Oxaliplatin·Capecitabine
Shanghai Henlius Biotech
Phase 3
550
California, Colorado, Florida, Illinois, Iowa, Missouri, Nebraska, Nevada
2024-11-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-11-21
Recruiting
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
NCT06740526IgA Nephropathy
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
25
Colorado, Massachusetts, South Dakota, Texas
2024-11-19
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
DrugAlisertib
Puma Biotechnology, Inc.
Phase 2
225
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-11-19
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2024-11-19
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
125
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-18
Recruiting
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378Chronic Granulomatous Disease (CGD)
Ensoma
Observational
60
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-11-18
Active, closed
Evaluation of a Simple-Prep Controlled Embolic
NCT06453642Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
Fluidx Medical Technology, Inc.
Not applicable
114
California, Colorado, Illinois, Indiana, Minnesota, Missouri, New York, North Carolina
2024-11-18
Recruiting
Evaluation of Pulsed Field Ablation of the Posterior Nasal Nerve for Chronic Rhinitis
NCT06598319Chronic Rhinitis
Aventix Medical Inc.
Not applicable
30
Colorado, Mississippi, Texas
2024-11-15
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
DrugRimegepant
Pfizer
Phase 3
200
Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-11-15
Recruiting
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
NCT06619587Solid Tumor
Genentech, Inc.
Phase 1
410
California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Michigan, New York
2024-11-14
Recruiting
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
NCT06422923Epilepsy, Temporal Lobe
DrugNRTX-1001
Neurona Therapeutics
Phase 1/2
10
Arkansas, California, Colorado, Illinois, Iowa, New York, North Carolina, Oregon
2024-11-14
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Iowa
2024-11-12
Active, closed
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
NCT06686654Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Sanofi Pasteur, a Sanofi Company
Phase 1/2
1,530
Arizona, California, Colorado, District of Columbia, Florida, Idaho, Kansas, Maryland
2024-11-11
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
DrugLP352
Longboard Pharmaceuticals
Phase 3
367
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2024-11-11
Active, closed
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
NCT06614192Metastatic Colorectal Cancer
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
74
California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-11-08
Active, closed
Efficacy and Safety of VDPHL01 in Males With AGA
NCT06724614Androgenetic Alopecia, AGA, Male Pattern Baldness
DrugVDPHL01
Veradermics, Inc.
Phase 2/3
480
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-11-06
Recruiting
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
NCT06575192Breast Reconstruction
AbbVie
Phase 3
264
California, Colorado, Florida, Illinois, Maryland, Missouri, Nevada, New Jersey
2024-11-05
Recruiting
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
NCT06636383Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical Inc
Observational
140
California, Colorado, Connecticut, Michigan, North Carolina, Ohio, Pennsylvania, Texas
2024-11-04
Active, closed
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
NCT06076642Primary Immunodeficiency Diseases (PID)
Takeda
Phase 3
53
California, Colorado, Florida, Georgia, Illinois, Louisiana, New York, North Carolina
2024-11-04
Recruiting
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
NCT06596694Gastrointestinal Cancer
DrugPatritumab deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2
180
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Nevada, New York
2024-11-03
Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
NCT06544265B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
DrugSynKIR-310
Verismo Therapeutics
Phase 1
36
Colorado, Georgia, Kansas, New Jersey, Pennsylvania
2024-11-01
Active, closed
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383Obesity
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2024-11-01
Recruiting
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593Moderately to Severely Active Crohn Disease
DrugObefazimod
Abivax S.A.
Phase 2
212
Alabama, Arizona, California, Colorado, Florida, Illinois, Iowa, Massachusetts
2024-10-30
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
DrugsCemdisiran·Pozelimab
Regeneron Pharmaceuticals
Phase 3
975
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-10-30
Recruiting
The THOR IDE Study
NCT05916950Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD
Philips Clinical & Medical Affairs Global
Not applicable
155
California, Colorado, Florida, Iowa, Louisiana, Maine, Massachusetts, Michigan
2024-10-29
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
NCT06656390Advanced Cancer, Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Colorado, Florida, Louisiana, Tennessee
2024-10-24
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals
Phase 1/2
232
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Massachusetts
2024-10-24
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-10-24
Recruiting
Shoulder Innovations Clinical Data Registry
NCT06754150Shoulder Arthroplasty
Shoulder Innovations
Observational
2,500
Alabama, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Michigan
2024-10-23
Active, closed
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064Wet Age Related Macular Degeneration, wAMD
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2024-10-22
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422Carcinoma, Non-Small-Cell Lung
DrugsIntismeran autogene·Gemcitabine·Pemetrexed·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
680
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2024-10-21
Recruiting
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
NCT06430385Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Ionis Pharmaceuticals, Inc.
Phase 1/2
48
California, Colorado, Maryland, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2024-10-21
Active, closed
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)
DrugsTaxotere·Mevrometostat·Enzalutamide·Paclitaxel
Pfizer
Phase 3
600
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Maine
2024-10-21
Active, closed
Esprit BTK Post-Approval Study
NCT06656364Chronic Limb-Threatening Ischemia
Abbott Medical Devices
Not applicable
200
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-10-21
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Irinotecan Hydrochloride·Amivantamab·Oxaliplatin
Janssen Research & Development, LLC
Phase 3
1,000
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-18
Recruiting
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860Diabetic Peripheral Neuropathic Pain
DrugPregabalin
Vertex Pharmaceuticals Incorporated
Phase 2
300
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Michigan
2024-10-18
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
DrugEfgartigimod
argenx
Phase 3
69
Arizona, California, Colorado, Connecticut, District of Columbia, Illinois, Iowa, Louisiana
2024-10-18
Recruiting
J-Valve Transfemoral Pivotal Study
NCT06455787Aortic Valve Regurgitation, Aortic Valve Disease Mixed
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Not applicable
194
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-10-17
Active, closed
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsRMC-6236·Liposomal Irinotecan·Leucovorin·Irinotecan
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Florida, Hawaii, Illinois, Maryland, Massachusetts
2024-10-16
Active, closed
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
NCT06598462Eosinophilic Esophagitis (EoE)
DrugSolrikitug
Uniquity One (UNI)
Phase 2
184
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2024-10-16
Recruiting
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06549790Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences
Phase 1
124
California, Colorado, Delaware, Georgia, Minnesota, Ohio, Texas
2024-10-16
Recruiting
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms
DrugsFolfiri·Folfox·Bevacizumab
Janssen Research & Development, LLC
Phase 1
260
Arizona, Colorado, Florida, Indiana, Michigan, Washington
2024-10-15
Active, closed
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844Non-small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Vinorelbine·Rilvegostomig·Etoposide
AstraZeneca
Phase 3
25
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2024-10-15
Rows per page Showing 701–800 of 2068
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/colorado?page=8

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,068 of those studies with a site in Colorado.

How many clinical trials are recruiting in Colorado?

1,024 of the 2,068 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 29 have not yet opened recruitment, 950 are active but closed to new participants, and 65 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.